



FINANCIAL TEAR SHEET

CORPORATE PROFILE

At PRA Health Sciences, we work side-by-side with our clients, to move drug discovery forward, and to help them develop life-saving and life- improving drugs. For more than 30 years, we’ve been helping to bring to market everything from niche treatments and therapies to blockbuster drugs. Providing comprehensive Phase I-IV biopharmaceutical drug development in ove countries, we are dedicated to being innovative, and to delivering unmatched scientific expertise that improves the drug develop process.

We help change people’s lives for the better every single day. It’s what we are passionate about.

STOCK QUOTE & CHART

PRAH (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Financial Status Indicator	C
Price	\$96.61
Change (%)	▼ 3.99 (3.97%)
Volume	145,424
52 Week Low	\$79.03
Market Cap	\$6,536,499,486
Rolling EPS	1.25
PE Ratio	80.1779
Shares Outstanding	64,975,144
Data as of 11/19/18 4:00 p.m. ET	



NEWS & EVENTS

Date	Title
------	-------

There are currently no events scheduled.

10/31/18	PRA Health Sciences, Inc. Reports Third Quarter 2018 Results and Updates 2018 Guidance
09/25/18	PRA Health Sciences to Report Third Quarter 2018 Earnings
08/07/18	PRA Health Sciences, Inc. Announces Pricing of Secondary Offering of 6,500,000 Shares of Common Stock

SEC FILINGS

Filing Date	Form
11/06/18	10-Q
10/31/18	8-K
08/20/18	4
08/20/18	8-K

BOARD OF DIRECTORS

Colin Shannon	Chairman of the Board
Jeffrey T. Barber	Director
Alexander G. Dickinson	Director
Linda S. Graiss, M.D.	Director
Max C. Lin	Director
James C. Momtazee	Director
Matthew P. Young	Director

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)